Mymetics Corp (MYMX)

[bow-tie]

Bill & Melinda Gates Foundation Discovery Humabs BioMed Rabies mABs Infectious Diseases Rabies Infection Licensed to Indian Immunologicals Ltd. Humabs BioMed S. aureus mAb Bacterial Infection S. aureus Infection Exclusively licensed to MedImmune

https://www.swissbiotech.org/wp-content/uploads/2019/04/sba-members-pipeline-201802-web-1.pdf

MAb-114 is the lead from a series of lyophilized human IgG1 MAbs also targeting the Zaire ebolavirus glycoprotein. It was isolated and characterized in Switzerland at the Institute for Research in Biomedicine in collaboration with Humabs Biomed SA, a subsidiary of Vir Biotechnology Inc., of San Francisco.